2018 February | The Journal of Targeted Therapies in Cancer

Abscopal Effect of Radiotherapy: Reality or Urban Legend?

February 20, 2018

Clinical Articles

IN THIS ISSUE, INVESTIGATORS FROM Emory Winship Cancer Institute describe their experience with the so-called “abscopal effect,” which describes the ability of locally delivered radiation therapy to trigger distant antitumor effects. R. H. Mole, BM, FRCP, first coined the term abscopal effect as “an action at a distance from the irradiated volume but within the same organism” in 1953.

Elevated Risk of Cardiovascular Adverse Events Identified in Meta-Analysis of Carfilzomib Studies

February 19, 2018

Clinical Articles

A meta-analysis and systemic review specifically assessing carfilzomib-associated cardiovascular adverse events suggests an elevated risk in patients with multiple myeloma who are taking the proteasome inhibitor.

Neoadjuvant Chemotherapy Considerations in Triple-Negative Breast Cancer

February 15, 2018

Clinical Articles

The optimal neoadjuvant chemotherapy regimen in triple-negative breast cancer has not been clearly defined. Achieving a pathologic complete response provides important prognostic information, and, especially in TNBC, is considered a surrogate endpoint for event-free survival.

Model Identifies Risk of Progression in Smoldering Multiple Myeloma With Greater Precision

February 15, 2018

Clinical Articles

Using next-generation squencing methods, researchers are attempting to combine clinical and genomic biomarkers to identify patients with smoldering multiple myeloma who are at high risk for disease progression.

Abscopal Effect Induction Among Patients With Metastatic Non-Small Cell Lung Cancer

February 14, 2018

Clinical Articles

The prognosis for patients with metastatic non–small cell lung cancer (NSCLC) is poor. However, with recent trials showing improved overall survival with checkpoint inhibitors compared with standard chemotherapy, disease management is changing.